Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 11 selected

Guidance programme

Showing 1 to 50 of 417

TitleReference numberPublishedLast updated
Sinusitis (acute): antimicrobial prescribingNG79
Cataracts in adults: managementNG77
Cystic fibrosis: diagnosis and managementNG78
Hepatitis B (chronic): diagnosis and managementCG165
Immunosuppressive therapy for kidney transplant in adultsTA481
Immunosuppressive therapy for kidney transplant in children and young peopleTA482
Tofacitinib for moderate to severe rheumatoid arthritisTA480
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphomaTA478
Reslizumab for treating severe eosinophilic asthmaTA479
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the kneeTA477
Faltering growth: recognition and management of faltering growth in childrenNG75
Cetuximab and panitumumab for previously untreated metastatic colorectal cancerTA439
Type 2 diabetes: prevention in people at high riskPH38
Pembrolizumab for advanced melanoma not previously treated with ipilimumabTA366
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumabTA357
Fertility problems: assessment and treatmentCG156
Sorafenib for treating advanced hepatocellular carcinomaTA474
Dimethyl fumarate for treating moderate to severe plaque psoriasisTA475
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancerTA476
Psoriasis: assessment and managementCG153
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neckTA473
Vitamin D: supplement use in specific population groupsPH56
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal)TA468
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)TA469
Holoclar for treating limbal stem cell deficiency after eye burnsTA467
Pemetrexed for the maintenance treatment of non-small-cell lung cancerTA190
Developmental follow-up of children and young people born pretermNG72
Cabozantinib for previously treated advanced renal cell carcinomaTA463
Baricitinib for moderate to severe rheumatoid arthritisTA466
Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutritionCG32
Adalimumab and dexamethasone for treating non-infectious uveitisTA460
Roflumilast for treating chronic obstructive pulmonary diseaseTA461
Nivolumab for treating relapsed or refractory classical Hodgkin lymphomaTA462
Parkinson's disease in adultsNG71
Constipation in children and young people: diagnosis and managementCG99
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopleTA455
Ustekinumab for moderately to severely active Crohn's disease after previous treatmentTA456
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)TA452
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)TA453
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA454
Air pollution: outdoor air quality and healthNG70
Eliglustat for treating type 1 Gaucher diseaseHST5
Etelcalcetide for treating secondary hyperparathyroidismTA448
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive diseaseTA449
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemiaTA450
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemiaTA451
Spondyloarthritis in over 16s: diagnosis and managementNG65
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDsTA445

Results per page

  1. 10
  2. 25
  3. 50
  4. All